{"id":"W2984927918","doi":"10.1200/jco.19.00172","title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":772,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Seagen (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Exelixis; Karyopharm Therapeutics; MEI Pharma; Astex Pharmaceuticals; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Kite Pharma; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bendamustine; Rituximab; Neutropenia; Hazard ratio; Cohort; Diffuse large B-cell lymphoma; Transplantation; Gastroenterology; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001771317,0.0001724098,0.001712863,0.0001894964,0.00002092021,0.000007734182,0.0001636982,0.0005401575,0.0004663332],"category_scores_gemma":[0.00191558,0.0001037566,0.0005308267,0.0001673091,0.00006186616,0.00008588007,0.00006375115,0.0005456982,0.0003472771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006938007,"about_ca_system_score_gemma":0.002775801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003192472,"about_ca_topic_score_gemma":0.00007299961,"domain_scores_codex":[0.9963262,0.0004022768,0.002335361,0.0002390859,0.0003661171,0.000330931],"domain_scores_gemma":[0.994682,0.003031228,0.001393656,0.0003100442,0.0001785994,0.0004045453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01840059,0.09399652,0.7667812,0.0000669388,0.0003347149,0.007812946,0.0002529161,0.000002027659,0.000243529,0.0001855405,0.008129993,0.1037931],"study_design_scores_gemma":[0.1362647,0.02074762,0.6246415,0.0001577057,0.0001967162,0.0003366221,0.0001754876,0.00006541247,0.0001013126,0.00006105538,0.2171507,0.0001011676],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854438,0.000961564,0.000002306253,0.00259892,0.001642978,0.0002529017,0.000003070495,0.000009594343,0.009084875],"genre_scores_gemma":[0.9916303,0.0011457,0.0008831769,0.00350506,0.0005739271,0.000004158208,0.000002981628,0.00002283489,0.002231885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2090207,"threshold_uncertainty_score":0.5106022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06801833353446632,"score_gpt":0.4233675724693748,"score_spread":0.3553492389349084,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}